Xaliproden

Xaliproden (nome in codice SR57746 ) è un farmaco che agisce come un 5HT 1A agonista .^[1]Ha effetti neuroprotettivi e neurotrofico ein vitro,^[2]^[3] ed è stato proposto per l'uso nel trattamento di diverse malattie neurodegenerative compresa sclerosi laterale amiotrofica (ALS)^[4] e la malattia di Alzheimer.^[5]

Lo sviluppo di xaliproden, in queste due indicazioni, è stato interrotto nel 2007, a seguito dell'analisi dei dati di fase III; mentre continua ad essere studiato per il trattamento della neuropatia periferica indotta dalla chemioterapia.^[6]^[7]

Note

^ MAPK activation via 5-hydroxytryptamine 1A receptor is involved in the neuroprotective effects of xaliproden, in International journal of immunopathology and pharmacology, vol. 18, n. 1, 2005, pp. 21–31, PMID 15698508.
^ Effect of the neuroprotective compound SR57746A on nerve growth factor synthesis in cultured astrocytes from neonatal rat cortex, in British Journal of Pharmacology, vol. 127, n. 1, 1999, pp. 139–44, DOI:10.1038/sj.bjp.0702545, PMID 10369466.
^ Effect of the nonpeptide neurotrophic compound SR 57746A on the phenotypic survival of purified mouse motoneurons, in British Journal of Pharmacology, vol. 128, n. 7, 1999, pp. 1385–92, DOI:10.1038/sj.bjp.0702910, PMID 10602316.
^ Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials, in Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, vol. 5, n. 2, 2004, pp. 107–17, DOI:10.1080/14660820410019602, PMID 15204012.
^ Lemaire L, Fournier J, Ponthus C, Le Fur Y, Confort-Gouny S, Vion-Dury J, Keane P, Cozzone P., Magnetic resonance imaging of the neuroprotective effect of xaliproden in rats, in Invest Radiol, vol. 37, n. 6, 2002, pp. 321–7, DOI:10.1097/00004424-200206000-00003, PMID 12021588.
^ Xaliproden lessens oxaliplatin-mediated neuropathy, in The lancet oncology, vol. 7, n. 4, 2006, p. 288, DOI:10.1016/S1470-2045(06)70639-8, PMID 16598880.
^ Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies, in European journal of cancer (Oxford, England : 1990), vol. 44, n. 11, 2008, pp. 1507–15, DOI:10.1016/j.ejca.2008.04.018, PMID 18571399.

[1] MAPK activation via 5-hydroxytryptamine 1A receptor is involved in the neuroprotective effects of xaliproden, in International journal of immunopathology and pharmacology, vol. 18, n. 1, 2005, pp. 21–31, PMID 15698508.

[2] Effect of the neuroprotective compound SR57746A on nerve growth factor synthesis in cultured astrocytes from neonatal rat cortex, in British Journal of Pharmacology, vol. 127, n. 1, 1999, pp. 139–44, DOI:10.1038/sj.bjp.0702545, PMID 10369466.

[3] Effect of the nonpeptide neurotrophic compound SR 57746A on the phenotypic survival of purified mouse motoneurons, in British Journal of Pharmacology, vol. 128, n. 7, 1999, pp. 1385–92, DOI:10.1038/sj.bjp.0702910, PMID 10602316.

[4] Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials, in Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, vol. 5, n. 2, 2004, pp. 107–17, DOI:10.1080/14660820410019602, PMID 15204012.

[5] Lemaire L, Fournier J, Ponthus C, Le Fur Y, Confort-Gouny S, Vion-Dury J, Keane P, Cozzone P., Magnetic resonance imaging of the neuroprotective effect of xaliproden in rats, in Invest Radiol, vol. 37, n. 6, 2002, pp. 321–7, DOI:10.1097/00004424-200206000-00003, PMID 12021588.

[6] Xaliproden lessens oxaliplatin-mediated neuropathy, in The lancet oncology, vol. 7, n. 4, 2006, p. 288, DOI:10.1016/S1470-2045(06)70639-8, PMID 16598880.

[7] Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies, in European journal of cancer (Oxford, England : 1990), vol. 44, n. 11, 2008, pp. 1507–15, DOI:10.1016/j.ejca.2008.04.018, PMID 18571399.

[1]

[2]

[3]

[4]

[5]

[6]

[7]